Form 4: AtriCure Executive Vinayak Doraiswamy Reports Stock Transactions

Vinayak Doraiswamy, Chief Scientific Officer of AtriCure, Inc., reports acquisition and disposal of company stock related to restricted stock and performance share awards.

Summary

• Vinayak Doraiswamy, Chief Scientific Officer of AtriCure, Inc., filed a Form 4 detailing changes in beneficial ownership of the company's stock.
• On March 1, 2025, Doraiswamy acquired 19,359 shares of common stock through a Restricted Stock Award under the 2023 Stock Incentive Plan, with one-third of the shares vesting annually over three years.
• He also acquired 6,579 shares through the vesting and release of a Performance Share Award under the same plan, as company performance goals and service period requirements were met.
• Additionally, Doraiswamy disposed of 9,672 shares to satisfy tax withholding obligations related to the vesting of previous stock awards at a price of $38.74 per share.
• Following these transactions, Doraiswamy beneficially owns 76,050 shares of AtriCure common stock.

Sentiment

Score: 6

Explanation: Neutral sentiment as the document primarily reports routine stock transactions related to executive compensation. The vesting of performance shares is a slightly positive indicator.

Positives

• The vesting of performance share awards indicates that the company met its performance goals.
• The acquisition of shares through restricted stock awards aligns the executive's interests with the company's long-term success.

Negatives

• The disposal of shares to cover tax obligations, while common, slightly reduces the executive's holdings.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the stock transactions of company insiders. This filing indicates standard compensation practices involving stock awards and tax obligations.

Stakeholder Impact

• The transactions have a minor impact on shareholders as they reflect standard executive compensation practices.

Key Dates